Elise M O'Connell1, Sarah Harrison1, Eric Dahlstrom2, Theodore Nash3, Thomas B Nutman1. 1. National Institute of Allergy and Infectious Diseases (NIAID), Laboratory of Parasitic Diseases (LPD), Helminth Immunology Section, Bethesda, Maryland. 2. NIAID, Research Technologies Branch, Bethesda, Maryland. 3. NIAID, LPD, Clinical Parasitology Section.
Abstract
BACKGROUND: Treatment of subarachnoid neurocysticercosis (NCC) is complicated, and assays that can guide treatment are not widely available. The reproducibility and scalability of molecular-based biomarkers would be of great use. METHODS: The Taenia solium genome was mined and primers and probes were designed to target repeats with the highest coverage; the most sensitive, specific, and efficient repeat (TsolR13) was selected for clinical testing. We tested 46 plasma samples and 36 cerebral spinal fluid (CSF) samples taken from patients with subarachnoid or ventricular disease using quantitative polymerase chain reaction (qPCR). RESULTS: The analytic sensitivity of TsolR13 was 97.3% at 240 attograms (ag) of T. solium genomic DNA and 100% analytic specificity. The clinical sensitivity in detecting active subarachnoid or ventricular disease in symptomatic patients was 100% in CSF and 81.3% in plasma. The predictive ability to distinguish active from cured disease was better for CSF (94.4% of those cured had negative qPCR results) than for plasma (86.7% of those cured tested negative). Some subjects also had plasma DNA detectable intermittently for years after being cured. Overall, the test performance was equivalent to T. solium antigen detection. CONCLUSIONS: A qPCR test for the detection of the highly repetitive Tsol13 sequence has been developed and shown to be highly sensitive and specific for NCC, but also useful as a test of cure in CSF and for the definitive diagnosis of NCC in plasma. Published by Oxford University Press for the Infectious Diseases Society of America 2019.
BACKGROUND: Treatment of subarachnoid neurocysticercosis (NCC) is complicated, and assays that can guide treatment are not widely available. The reproducibility and scalability of molecular-based biomarkers would be of great use. METHODS: The Taenia solium genome was mined and primers and probes were designed to target repeats with the highest coverage; the most sensitive, specific, and efficient repeat (TsolR13) was selected for clinical testing. We tested 46 plasma samples and 36 cerebral spinal fluid (CSF) samples taken from patients with subarachnoid or ventricular disease using quantitative polymerase chain reaction (qPCR). RESULTS: The analytic sensitivity of TsolR13 was 97.3% at 240 attograms (ag) of T. solium genomic DNA and 100% analytic specificity. The clinical sensitivity in detecting active subarachnoid or ventricular disease in symptomatic patients was 100% in CSF and 81.3% in plasma. The predictive ability to distinguish active from cured disease was better for CSF (94.4% of those cured had negative qPCR results) than for plasma (86.7% of those cured tested negative). Some subjects also had plasma DNA detectable intermittently for years after being cured. Overall, the test performance was equivalent to T. solium antigen detection. CONCLUSIONS: A qPCR test for the detection of the highly repetitive Tsol13 sequence has been developed and shown to be highly sensitive and specific for NCC, but also useful as a test of cure in CSF and for the definitive diagnosis of NCC in plasma. Published by Oxford University Press for the Infectious Diseases Society of America 2019.
Authors: H Yera; D Dupont; S Houze; M Ben M'rad; F Pilleux; A Sulahian; C Gatey; F Gay Andrieu; J Dupouy-Camet Journal: J Clin Microbiol Date: 2011-10-05 Impact factor: 5.948
Authors: Rodrigo Bazan; Pedro Tadao Hamamoto Filho; Gustavo José Luvizutto; Hélio Rubens de Carvalho Nunes; Newton Satoru Odashima; Antônio Carlos Dos Santos; Jorge Elias Júnior; Marco Antônio Zanini; Agnès Fleury; Osvaldo Massaiti Takayanagui Journal: PLoS Negl Trop Dis Date: 2016-11-09
Authors: Nils Pilotte; Marina Papaiakovou; Jessica R Grant; Lou Ann Bierwert; Stacey Llewellyn; James S McCarthy; Steven A Williams Journal: PLoS Negl Trop Dis Date: 2016-03-30
Authors: Sarah Harrison; Lauren Thumm; Theodore E Nash; Thomas B Nutman; Elise M O'Connell Journal: Clin Infect Dis Date: 2021-05-04 Impact factor: 9.079